ALX Oncology
Susan Vermeir has a wealth of experience in regulatory affairs, beginning their career as a Project Leader at BioResearch Laboratories, Inc. Susan later went on to hold various roles at companies such as Genentech Inc., InterMune Inc., and Pyxis Enterprises, L.L.C. Currently, Susan serves as the Vice President of Regulatory Affairs at ALX Oncology Inc., a clinical-stage immuno-oncology company focusing on developing therapies to block the CD47 checkpoint mechanism utilized by cancer cells to evade the immune system. Susan's expertise lies in guiding product development through various regulatory pathways in the pharmaceutical and biotechnology industries.
This person is not in any offices
ALX Oncology
ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system.